Multiple sclerosis patients and COVID-19

被引：0
作者：
Hubert Mado
Monika Adamczyk-Sowa
机构：
[1] Medical University of Silesia in Katowice,Department of Neurology, Faculty of Medical Sciences in Zabrze
[2] Poland,undefined
来源：
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | / 57卷
关键词：
Multiple sclerosis; MS; COVID-19; SARS-CoV-2; DMT;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine. Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs. The aim of this article is to discuss what is currently known about the severity of COVID-19 in MS patients.
引用
收藏
相关论文
共 30 条
[1]  
Wu Z(2020)Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China JAMA. 323 1239-952
[2]  
McGoogan J(2020)Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies JAMA Neurol. 77 184-797
[3]  
Luna G(2021)SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy Clin Neurol Neurosurg. 201 106451-undefined
[4]  
Alping P(2020)Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis JAMA Neurol. 77 1079-undefined
[5]  
Burman J(2020)Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic Neurology. 94 949-undefined
[6]  
Fink K(2020)SARS-CoV -2 and multiple sclerosis: not all immune depleting DMTs are equal or bad Ann Neurol. 87 794-undefined
[7]  
Fogdell-Hahn A(undefined)undefined undefined undefined undefined-undefined
[8]  
Gunnarsson M(undefined)undefined undefined undefined undefined-undefined
[9]  
Adamczyk-Sowa M(undefined)undefined undefined undefined undefined-undefined
[10]  
Mado H(undefined)undefined undefined undefined undefined-undefined
123